Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Net Income towards Common Stockholders: 2009-2024

Historic Net Income towards Common Stockholders for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Dec 2024 value amounting to $163.4 million.

  • Catalyst Pharmaceuticals' Net Income towards Common Stockholders rose 20.28% to $52.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $217.1 million, marking a year-over-year increase of 65.79%. This contributed to the annual value of $163.4 million for FY2024, which is 174.43% up from last year.
  • Latest data reveals that Catalyst Pharmaceuticals reported Net Income towards Common Stockholders of $163.4 million as of FY2024, which was up 174.43% from $59.5 million recorded in FY2023.
  • Catalyst Pharmaceuticals' 5-year Net Income towards Common Stockholders high stood at $163.4 million for FY2024, and its period low was $39.5 million during FY2021.
  • Its 3-year average for Net Income towards Common Stockholders is $102.0 million, with a median of $83.1 million in 2022.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first tumbled by 47.35% in 2021, then skyrocketed by 174.43% in 2024.
  • Yearly analysis of 5 years shows Catalyst Pharmaceuticals' Net Income towards Common Stockholders stood at $75.0 million in 2020, then slumped by 47.35% to $39.5 million in 2021, then surged by 110.42% to $83.1 million in 2022, then fell by 28.34% to $59.5 million in 2023, then skyrocketed by 174.43% to $163.4 million in 2024.